Pharmaceuticals
Harbour BioMed Announces Dosing of First Patient in Phase I Trial of B7H4x4-1BB Bispecific Antibody in the United States
CAMBRIDGE, Mass., ROTTERDAM and SUZHOU, China, Oct. 20, 2022 /PRNewswire/ -- Harbour BioMed ("HBM", HKEX: 02142) announced that, it has successfully completed the dosing of first patient in the global phase I trial of B7H4x4-1BB bispecific antibody HBM7008 inthe United States. This study will eva...
2022-10-20 16:20
2161
AASLD 2022 | Ascentage Pharma to Announce Results from First-in-Human Study of IAP Antagonist APG-1387 in an Oral Report at the AASLD Annual Meeting
SUZHOU, China and ROCKVILLE, Md., Oct. 19, 2022 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced that it will release results from the Phase I fir...
2022-10-20 07:16
1966
STANDIGM TO ATTEND BIO-EUROPE® 2022
Standigm will present AI-driven drug discovery technology at the conference
CAMBRIDGE, England, Oct. 18, 2022 /PRNewswire/ -- Standigm
2022-10-19 01:50
2028
CARsgen Announces NDA Acceptance of BCMA CAR T Zevor-cel (CT053) by China NMPA
SHANGHAI, Oct. 18, 2022 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announces thatthe National Medical Products Administration (NMPA) ofChina has a...
2022-10-18 20:50
3445
Zhiyi Biotech Received Clinical Approval from U.S. FDA for SK10 in Chemotherapy-induced Diarrhea
GUANGZHOU, China, Oct. 18, 2022 /PRNewswire/ -- Zhiyi Biotech announced that FDA has approved the Company's Investigational New Drug (IND) application to develop SK10 (InactivatedBacteroides fragilis) for the treatment of Chemotherapy-induced Diarrhea (CID) . The approval of this IND authorizes Z...
2022-10-18 20:35
1327
Axiomtek Unleashes IP69K/IP66-Rated 10.4" Stainless Steel Fanless Touch Panel Computer for Food Processing Industry - GOT810-316
TAIPEI, Oct. 17, 2022 /PRNewswire/ -- Axiomtek – a world-renowned leader relentlessly devoted in the research, development and manufacture of series of innovative and reliable industrial computer products of high efficiency – is pleased to announce theGOT810-316, a 10.4-inch stainless steel fanle...
2022-10-18 11:41
1749
PENTAX Medical launches the C2 CryoBalloon(TM) Ablation System in Canada for the treatment of Barrett's Esophagus.
MISSISSAUGA, ON, Oct. 14, 2022 /PRNewswire/ -- PENTAX Medical, a healthcare industry leader in diagnostic and therapeutic endoscopy solutions, announced today the Canadian launch of the C2 CryoBalloon™ Ablation System for the treatment of Barrett's Esophagus. "With the launch of C2 CryoBalloon A...
2022-10-15 03:57
2108
Tianfu International Biocity: Build Global Bioindustry-city
CHENGDU, China, Oct. 14, 2022 /PRNewswire/ -- On Oct.10, Chengdu Tianfu Global International Biocity saw the signing of ten project agreements totalling nearly 9B CNY in value and covering modern biopharmaceuticals, innovative chemical drugs, sophisticated medical apparatuses and other important f...
2022-10-14 20:48
1710
Fosun Pharma's MSCI ESG Rating Upgraded to A
SHANGHAI, Oct. 13, 2022 /PRNewswire/ -- The world's leading index company Morgan Stanley Capital International ("MSCI") recently announced its latest annual Environmental, Social and Governance ("ESG") rating results. In recognition of its outstanding performance in ESG,MSCI upgraded the ESG rati...
2022-10-14 08:26
3686
Alterity Therapeutics Launches ATH434 Phase 2 Clinical Trial in Australia for the Treatment of Individuals with Multiple System Atrophy
Australia now open for study of rare, rapidly progressive Parkinsonian Disorder MELBOURNE, Australia and SAN FRANCISCO, Oct. 13, 2022 /PRNewswire/ -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying t...
2022-10-13 22:25
1835
Research Collaboration between Prof. Antonio Gasbarrini team at Gemelli Hospital and Asian Biotech companies, Coree and Dx&Vx
SEOUL, South Korea, Oct. 13, 2022 /PRNewswire/ -- According to International Diabetes Federation, approximately 537 million adults (20-79 years) are living with diabetes worldwide and 206 million adults of the Western Pacific region includingChina, Japan, and South Korea have diabetes in 2021. St...
2022-10-13 21:00
1832
Harbour BioMed Announces Upcoming Poster Presentations at the 37th Society for Immunotherapy of Cancer Annual Meeting
CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SUZHOU, China, Oct. 13, 2022 /PRNewswire/ -- Harbour BioMed (the "Company", HKEX: 02142), a global biopharmaceutical company committed to the discovery, development, and commercialization of novel antibody therapeutics focusing on oncology and immunol...
2022-10-13 19:05
1846
Samsung Biologics obtains three global ISO certifications
* Receives accreditation for information security management system, information security in cloud services, and anti-bribery management systems * First global CDMO to be ISO 27001 and ISO 27017 certified * Earns Excellence Award for Integrated Management System from BSI for its performance ...
2022-10-13 19:00
1893
Guiyang's Wudang district shines in pharma sector
GUIYANG, Oct. 12, 2022 /PRNewswire/ -- A news report from chinadaily.com.cn: Southwest China's Guizhou province – one of the four main regions for traditional Chinese medicine materials production inChina – has abundant medicine resources and a long history in ethnic medicine, and these days, it...
2022-10-13 10:12
1371
Great Bay Bio Announces Official Launch of Site-Specific Integration Platform for Cell Line Development, AlfaCell®
HONG KONG, Oct. 11, 2022 /PRNewswire/ -- Great Bay Bio (hereinafter referred to as "GBB") today announces the official launch of its self-developed AI-enabled site-specific integration platform for cell line development (CLD), AlfaCell®. AlfaCell® platform has pioneered to integrate GBB's proprie...
2022-10-11 20:40
2213
HanAll's Licensed Partner in China Enters Sublicense Agreement with CSPC to Further Accelerate Development of Batoclimab
* Harbour BioMed, HanAll's licensed partner in China, signed a sublicense agreement with CSPC NBP Pharmaceutical for batoclimab, an FcRn compound originally discovered and developed by HanAll Biopharma * Batoclimab is one of the most advanced FcRn inhibitors being developed in Greater China, ...
2022-10-11 19:00
1733
Samsung Biologics unlocks additional capacity for production at its newest Plant 4
* Plant 4 commences GMP operations within just 23 months since groundbreaking, as planned * Partial operations add fresh biomanufacturing capacity of 60,000 liters * Plant 4's total capacity of 240,000 liters to be ready early next year INCHEON,South Korea, Oct. 11, 2022 /PRNewswire/ -- Sams...
2022-10-11 19:00
1930
IASO Biotherapeutics and Cabaletta Bio Announce Exclusive Worldwide License Agreement for Clinically Validated CD19 Binder
PHILADELPHIA and SAN JOSE, Calif. and NANJING and SHANGHAI, China, Oct. 11, 2022 /PRNewswire/ -- IASO Biotherapeutics ("IASO Bio"), a clinical-stage biopharmaceutical company engaged in discovering, developing, and manufacturing innovative medicines and Cabaletta Bio, Inc. (Nasdaq: CABA), a clini...
2022-10-11 19:00
2264
Antengene Announces Upcoming Presentations at the 2022 Society for Immunotherapy of Cancer Annual Meeting
* Oral presentation highlights preclinical data of ATG-031, an in-house discovered anti-CD24 monoclonal antibody * Three poster presentations showcase preclinical data of ATG-101, a PD-L1/4-1BB bispecific antibody developed in-house, ATG-018, an ATR inhibitor discovered in-house, and ATG-027,...
2022-10-08 10:43
2712
First patient treated in Clarity's therapeutic prostate cancer trial
Highlights * Clarity Pharmaceuticals recruits and treats its first patient in the therapeutic phase of its SAR-bisPSMA theranostic clinical trial SECuRE (NCT04868604)[1] investigating Targeted Copper Theranostics (TCTs) in patients with metastatic castrate-resistant prostate cancer (mCRPC) ...
2022-10-07 21:06
2191
Week's Top Stories
Most Reposted
Agoda Launches Agoda Impact Lab at ASEAN Tourism Forum
[Picked up by 318 media titles]
2026-01-29 15:06
Agoda Launches Open-Source API Agent to Simplify MCP Server Integrations
[Picked up by 309 media titles]
2026-01-27 13:00
Nokia Strengthens Edge AI Capabilities Through Strategic Collaboration with Blaize on Hybrid Inference Solutions Across Asia Pacific Regions
[Picked up by 294 media titles]
2026-01-27 18:00
Singapore Airshow 2026 Milestone Edition: 20 Years of Shaping the Aerospace Landscape as Asia-Pacific Drives Global Growth
[Picked up by 284 media titles]
2026-02-01 19:35Multi-Award Winning Phuket Marriott Resort & Spa, Merlin Beach: Voted Top 3 Best Family Resort
[Picked up by 283 media titles]
2026-01-30 08:00
